Compared with placebo, both tirzepatide (HR 0.78, 95% CI 0.660.93) and the GLP-1RA class (HR 0.85, 95% CI 0.800.91) were associated with lower risk of MACE, with moderate heterogeneity (Q = 13.9 [ p = 0.126], 2 = 0.0040, I 2 = 35.26%)
I'm convinced that it like permanently messed up my spelling, because I have a tendency to spell things the British way
Disclaimer: Pricing is subject to change at any time
"As more people begin using these treatments, were seeing a growing awareness of how they impact more than just a patients weight, particularly around peoples sex drive, intimacy, and sexual satisfaction." He went on to explain that as well as suppressing appetite, GLP-1s also influence the brain's reward system, 'particularly dopamine pathways.' Murphy continued: "Dopamine is central to sexual desire, pleasure, and motivation, so with GLP-1s blunting dopamine activity, it not only reduces cravings for food, but it can also reduce sexual cravings and emotional reward from intimacy." While it's unclear how many GLP-1 users experience a lack of libido, several common side effects have been heavily reported, including nausea, vomiting, diarrhoea, stomach pain and constipation